Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
This research is investigating age-related macular degeneration (AMD), a common cause of vision loss. Specifically, it focuses on the 'atrophic' form, for which there's no treatment yet. We know that certain immune cells called monocytes build up in the eyes of people with atrophic AMD. These cells can release substances that might harm eye cells. This study aims to see if monocytes from people with atrophic AMD survive longer on eye cells in a lab compared to monocytes from healthy individuals. By understanding if these immune cells behave differently, and by identifying any harmful substances they produce, researchers hope to discover new ways to treat atrophic AMD and protect vision.
At a glance
What is this study about?
Imagine your eye like a very sophisticated camera. The back of this camera has a special light-sensitive layer called the retina. Right behind the retina is a supportive layer called the retinal pigment epithelium (RPE), which helps keep the retina healthy. Age-related macular degeneration (AMD) is a common eye condition that affects a part of your retina called the macula, which is responsible for sharp, central vision.
There are two main types of AMD. One, called the 'wet' or 'exudative' form, has treatments that can help. However, the other type, 'atrophic' or 'dry' AMD, currently has no specific treatment. In people with atrophic AMD, we've noticed that certain immune cells, called monocytes, tend to gather in the eye where they usually shouldn't be. These monocytes can release chemicals that might damage the RPE cells and the cells that detect light.
This study wants to understand if these monocytes from people with atrophic AMD survive better or act differently when placed on RPE cells in a lab setting, compared to monocytes from people without eye problems. If we find that these monocytes from atrophic AMD patients live longer or release more harmful chemicals, it could give us clues about why the condition develops and how to create new medicines to stop it or slow it down. It's like trying to find the specific problem in a plumbing system to fix a leak.
Key takeaways
- This study is about understanding atrophic (dry) AMD.
- It investigates how immune cells (monocytes) behave in AMD patients.
- The goal is to find clues for new treatments, as currently there are none for atrophic AMD.
- Participation involves providing a blood sample.
- There are no direct personal benefits or treatments provided.
- Your contribution could help future patients with AMD.
Who may be eligible?
To join this study, you need to be over 50 years old. We are looking for people who have age-related macular degeneration (AMD) in both eyes, or early AMD in one eye and atrophic AMD in the other. We are also looking for a group of people who have no eye problems to compare results with.
There are some reasons why you might not be able to join. For example, if you weigh less than 50kg, or if you are already taking part in another clinical trial. Also, if you have other long-term eye conditions besides AMD, or if you are taking certain medicines that affect your immune system, you might not be suitable.
People with diabetes or a history of certain eye treatments (called dynamic phototherapy) would also not be able to take part. It's important that you can understand and agree in writing to be part of the study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you male or female and over 50 years old?
- Do you have AMD in both eyes, or atrophic AMD in one eye with early AMD in the other, or no eye problems?
- Do you weigh 50kg or more?
- Are you NOT currently taking part in another clinical trial?
- Do you NOT have diabetes or other serious long-term eye conditions?
- Are you NOT taking medicines that significantly affect your immune system?
What does participation involve?
This study is mainly about collecting blood samples. You would provide a small blood sample, similar to what you might give for a routine blood test at your doctor's office. This blood will then be used in the lab to study the immune cells. You wouldn't need to take any new medication or have any special treatments as part of this study. The total duration of your involvement would be limited to the blood draw and any initial checks to make sure you are suitable.
Potential risks and benefits
Locations (2)
- Hôpital Edouard HerriotVerified postcodeLyon, France· Recruiting
- Service d'ophtalmologie-HOSPICES CIVILS DE LYON - Hôpital de la Croix-RousseVerified postcodeLyon, France· Recruiting
Common questions
What is 'atrophic AMD'?
Atrophic AMD is a type of age-related macular degeneration, often called 'dry' AMD, where cells in the back of your eye slowly break down, leading to gradual central vision loss. There are currently no specific treatments for it.
What are monocytes?
Monocytes are a type of white blood cell, which are part of your body's immune system. They help fight infections and clean up damaged cells.
Why is this study important?
This study aims to understand why certain immune cells might be harmful in atrophic AMD. This knowledge could help scientists develop new treatments for this condition, which currently has none.
Will I get any treatment in this study?
No, this is a research study, not a clinical trial testing a new treatment. Your participation involves providing a blood sample to help us understand the disease better.
How much blood will be taken?
A small amount of blood will be taken, similar to what you might give for a routine blood test at your doctor's office.
How to find out more
Thibaud Mathis, MD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.